Top

Published in:

01-12-2009 | Preclinical Study

Immunohistochemical validation of multiple phospho-specific epitopes for estrogen receptor α (ERα) in tissue microarrays of ERα positive human breast carcinomas

Authors: George P. Skliris, Brian G. Rowan, Mariam Al-Dhaheri, Christopher Williams, Sandy Troup, Sanela Begic, Michelle Parisien, Peter H. Watson, Leigh C. Murphy

Published in: Breast Cancer Research and Treatment | Issue 3/2009

Abstract

Estrogen receptor α (ERα) activity is regulated by phosphorylation at several sites. Recently several antibodies specific for individual phosphorylated sites within ERα have became available. Such antibodies potentially provide invaluable tools to gain insight into the relevance in vivo of phosphorylated ERα in human breast tumors. However, validation of these antibodies for immunohistochemistry in particular is necessary in the first instance. In this study we have investigated the usefulness of several antibodies generated to specific phosphorylated sites within ERα for immunohistochemistry of formalin-fixed, paraffin-embedded human breast cancer biopsy samples. As well, these data demonstrate for the first time, the detection of multiple phosphorylated ERα forms in breast cancer (P-S104/106-ERα, P-S118-ERα, P-S167-ERα, P-S282-ERα, P-S294-ERα, P-T311-ERα, and P-S559-ERα) suggesting the possibility that profiling of phosphorylated ERα isoforms might be useful in selecting subgroups of breast cancer patients that would benefit from endocrine therapy.

Weigel N, Moore N (2007) Steroid receptor phosphorylation: a key modulator of multiple receptor functions. Mol Endocrinol 21:2311–2319CrossRefPubMed

Lannigan D (2003) Estrogen receptor phosphorylation. Steroids 68(1):1–9. doi:10.1016/S0039-128X(02)00110-1 CrossRefPubMed

Chen D, Pace P, Coombes R, Ali S (1999) Phosphorylation of human estrogen receptor alpha by protein kinase A regulates dimerization. Mol Cell Biol 19:1002–1015PubMed

Michalides R, Griekspoor A, Balkenende A, Verwoerd D, Janssen L, Jalink K, Floore A, Velds A, Veer LVT, Neefjes J (2004) Tamoxifen resistance by a conformational arrest of the estrogen receptor alpha after PKA activation in breast cancer. Cancer Cell 5:597–605. doi:10.1016/j.ccr.2004.05.016 CrossRefPubMed

Lee H, Bai W (2002) Regulation of estrogen receptor nuclear export by ligand-induced and p38-mediated receptor phosphorylation. Mol Cell Biol 22:5835–5845. doi:10.1128/MCB.22.16.5835-5845.2002 CrossRefPubMed

Arnold S, Vorojeikina D, Notides A (1995) Phosphorylation of tyrosine 537 on the human estrogen receptor is required for binding to an estrogen response element. J Biol Chem 270(50):30205–30212. doi:10.1074/jbc.270.50.30205 CrossRefPubMed

Williams C, Smith CL, Rowan BG (2007) Identification of four novel phosphorylation sites in estrogen receptor α: impact on receptor-dependent gene expression and phosphorylation by protein kinase CK2. In: The Endocrine Society’s 89th annual meeting, Toronto, Canada, 2007, pp 2–258

Jiang J, Sarwar N, Peston D, Kulinskaya E, Shousha S, Coombes R, Ali S (2007) Phosphorylation of estrogen receptor-alpha at Ser167 is indicative of longer disease-free and overall survival in breast cancer patients. Clin Cancer Res 13:5769–5776. doi:10.1158/1078-0432.CCR-07-0822 CrossRefPubMed

Gee J, Robertson J, Gutteridge E, Ellis I, Pinder S, Rubini M, Nicholson R (2005) Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer. Endocr Relat Cancer 12(Suppl 1):S99–S111. doi:10.1677/erc.1.01005 CrossRefPubMed

10.

Murphy LC, Cherlet T, Adeyinka A, Niu Y, Snell L, Watson P (2004) Phospho-Serine-118 estrogen receptor-alpha detection in human breast tumors in vivo. Clin Cancer Res 10:1354–1359. doi:10.1158/1078-0432.CCR-03-0112 CrossRefPubMed

11.

Watson P, Snell L, Parisien M (1996) The NCIC-Manitoba Breast Tumor Bank: a resource for applied cancer research. CMAJ 155:281–283PubMed

12.

Snell L, Watson P (2006) Breast tissue banking: collection, handling, storage, and release of tissue for breast cancer research. Methods Mol Med 120:3–24PubMed

13.

Skliris G, Leygue E, Curtis-Snell L, Watson P, Murphy L (2006) Expression of oestrogen receptor-beta in oestrogen receptor-alpha negative human breast tumours. Br J Cancer 95:616–626. doi:10.1038/sj.bjc.6603295 CrossRefPubMed

14.

Al-Dhaheri M, Rowan B (2006) Application of phosphorylation site-specific antibodies to measure nuclear receptor signaling: characterization of novel phosphoantibodies for estrogen receptor alpha. Nucl Recept Signal 4:e007CrossRefPubMed

15.

Emberley E, Niu Y, Curtis L, Troup S, Mandal S, Myers J, Gibson S, Murphy L, Watson P (2005) The S100A7-c-Jun activation domain binding protein 1 pathway enhances prosurvival pathways in breast cancer. Cancer Res 65(13):5696–5702. doi:10.1158/0008-5472.CAN-04-3927 CrossRefPubMed

16.

Murphy L, Niu Y, Snell L, Watson P (2004) Phospho-Serine-118 estrogen receptor-alpha expression in primary human breast tumors in vivo is associated with better disease outcome in women treated with tamoxifen. Clin Cancer Res 10(17):5902–5906. doi:10.1158/1078-0432.CCR-04-0191 CrossRefPubMed

17.

Yamashita H, Nishio M, Kobayashi S, Ando Y, Sugiura H, Zhang Z, Hamaguchi M, Mita K, Fujii Y, Iwase H (2005) Phosphorylation of estrogen receptor alpha serine 167 is predictive of response to endocrine therapy and increases post relapse survival in metastatic breast cancer. Breast Cancer Res 7:R753–R764. doi:10.1186/bcr1285 CrossRefPubMed

18.

Sarwar N, Kim J, Jiang J, Peston D, Sinnett H, Madden P, Gee J, Nicholson R, Lykkesfeldt A, Shousha S et al (2006) Phosphorylation of ERalpha at serine 118 in primary breast cancer and in tamoxifen-resistant tumours is indicative of a complex role for ERalpha phosphorylation in breast cancer progression. Endocr Relat Cancer 13:851–861. doi:10.1677/erc.1.01123 CrossRefPubMed

19.

Barnes R, Parisien M, Murphy L, Watson P (2008) Influence of evolution in tumor biobanking on the interpretation of translational research. Cancer Epidemiol Biomarkers Prev 17:3344–3350CrossRefPubMed

20.

Murphy L, Weitsman G, Skliris G, Teh E, LI L, Peng B, Davie J, Ung K, Niu Y, Troup S et al (2006) Potential role of estrogen receptor alpha phosphorylation at serine 118 in human breast cancer in vivo. J Steroid Biochem Mol Biol 102:139–146. doi:10.1016/j.jsbmb.2006.09.021 CrossRefPubMed

21.

Weitsman G, Li L, Skliris G, Davie J, Ung K, Curtis-Snell L, Tomes L, Watson P, Murphy L (2006) Estrogen receptor-alpha phosphorylated at Serine 118 is present at the promoters of estrogen-regulated genes and is not altered due to Her2 over-expression. Cancer Res 66:10162–10170. doi:10.1158/0008-5472.CAN-05-4111 CrossRefPubMed

22.

Yang C, Xin H, Kelley J, Spencer A, Brautigan D, Paschal B (2007) Ligand binding to the androgen receptor induces conformational changes that regulate phosphatase interactions. Mol Cell Biol 27:3390–3404. doi:10.1128/MCB.02411-06 CrossRefPubMed

23.

Bergqvist J, Elmberger G, Ohd J, Linderholm B, Bjohle J, Hellborg H, Nordgren H, Borg A, Skoog L, Bergh J (2006) Activated ERK1/2 and phosphorylated oestrogen receptor alpha are associated with improved breast cancer survival in women treated with tamoxifen. Eur J Cancer 42:1104–1112. doi:10.1016/j.ejca.2006.01.028 CrossRefPubMed

24.

Zoubir M, Mathieu M, Mazouni C, Liedtke C, Corley L, Geha S, Bouaziz J, Spielmann M, Drusche F, Symmans W et al (2008) Modulation of ER phosphorylation on serine 118 by endocrine therapy: a new surrogate marker for efficacy. Ann Oncol 19:1402–1406. doi:10.1093/annonc/mdn151 CrossRefPubMed

Title: Immunohistochemical validation of multiple phospho-specific epitopes for estrogen receptor α (ERα) in tissue microarrays of ERα positive human breast carcinomas
Authors: George P. Skliris
Brian G. Rowan
Mariam Al-Dhaheri
Christopher Williams
Sandy Troup
Sanela Begic
Michelle Parisien
Peter H. Watson
Leigh C. Murphy
Publication date: 01-12-2009
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 3/2009
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-008-0267-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2009

Molecular characterization of circulating tumor cells in large quantities of contaminating leukocytes by a multiplex real-time PCR

Lack of large genomic deletions in BRIP1, PALB2, and FANCD2 genes in BRCA1/2 negative familial breast cancer

‘Minority report’: how best to analyze clinical trial data to address disparities

Prevalent breast cancer patients with a homozygous mutant status for CYP2D6*4: response and biomarkers in tamoxifen users

Prospective study of breast MRI in BRCA1 and BRCA2 mutation carriers: effect of mutation status on cancer incidence

Reporting of race and ethnicity in breast cancer research: room for improvement

Keynote webinar | Spotlight on antibody–drug conjugates in cancer